Lower Tacrolimus Dose Is Suitable For Living Donor Liver Transplantation With Small-For-Size Graft
Main Category: Transplants / Organ DonationsAlso Included In: Liver Disease / Hepatitis
Article Date: 27 Aug 2009 - 4:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Several studies have shown that living donor liver transplant (LDLT) recipients required smaller doses of tacrolimus compared with deceased donor liver transplant (DDLT) patients, which indicated that liver regeneration could affect the metabolism of tacrolimus in LDLT. In recent years, living donor liver transplantation in adult patients with SFS liver grafts has become increasingly accepted. However,there are few studies in the existing literature on tacrolimus dosage requirements in LDLT with SFS grafts which require adequate liver regeneration.
A research article published in the World Journal of Gastroenterology addresses this problem. The research team led by Professor Li from the Center of Liver Transplantation of Sichuan University collected the medical data from the Center of Liver Transplantation in West China Hospital of Sichuan University, which is one of the biggest centers for liver transplantation in China, to study tacrolimus dosage requirements and blood levels in LDLT recipients with SFS grafts. Previous studies have indicated a high variability of the optimal tacrolimus dose in LDLT. The current article further investigates the tacrolimus dosing requirements in SFS graft by comparing tacrolimus dosage requirements in patients who received a graft with adequate hepatic mass (Group N) and in patients who received a SFS graft (Group S) in LDLT.
The result of their study revealed that there was no difference in demographic characteristics, acute rejection rates, liver and renal function test results, or the number of potentially interacting medications administered between the groups. Moreover, Professor Li and colleagues recommended that relatively low tacrolimus doses should be administered to patients who receive living donor liver transplantation with SFS liver grafts.
The tacrolimus dosage requirements and blood levels in LDLT with SFS grafts were reported by Professor Li and colleagues in China, which have been previously neglected. These results demonstrate that low doses of tacrolimus may be required in SFS grafts in living donor liver transplantation, which will be a good guideline to follow for rational administration of tacrolimus in future LDLT recipients with SFS grafts.
Reference:
Liu F, Li Y, Lan X, Wei YG, Li B, Yan LN, Wen TF, Zhao JC,Xu MQ, Wang WT, Yang JY. Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts. World J Gastroenterol 2009; 15(31): 3931-3936 http://www.wjgnet.com/1007-9327/15/3931.asp
Source:
Lin Tian
World Journal of Gastroenterology
Visit our transplants / organ donations section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/162095.php>
APA
http://www.medicalnewstoday.com/releases/162095.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



